Benefits of the Polypill on Medication Adherence in the Primary and Secondary Prevention of Cardiovascular Disease: A Systematic Review

被引:9
|
作者
Lopez-Lopez, Jose P. [1 ,2 ]
Gonzalez, Ana Maria [1 ]
Lanza, Paola [1 ]
Lopez-Jaramillo, Patricio [1 ,3 ]
机构
[1] Univ Santander UDES, MASIRA Res Inst, Bucaramanga, Santander, Colombia
[2] Pontificia Univ Javeriana, Hosp Univ San Ignacio, Dept Internal Med, Cardiol Unit, Bogota, Colombia
[3] Univ Santander UDES, MASIRA Res Inst, Fac Ciencias Salud, Bloque G,Piso 6, Bucaramanga, Santander, Colombia
关键词
polypill; cardiovascular disease; hypertension; dyslipidemia; major cardiovascular events; DOSE COMBINATION TREATMENT; HIGH-RISK; BLOOD-PRESSURE; STRATEGY; TRIAL; DRUGS;
D O I
10.2147/VHRM.S421024
中图分类号
R6 [外科学];
学科分类号
1002 ; 100210 ;
摘要
Background: Higher medication adherence reduces the risk of new cardiovascular events. However, there are individual and health system barriers that lead to lower adherence. The polypill has demonstrated benefits in cardiovascular morbidity and mortality mainly driven by an increase in adherence. We aim to evaluate the impact of the polypill on adherence to cardiovascular medication, its efficacy and safety in cardiovascular disease (CVD) prevention. Methods: A systematic review following PRISMA guidelines was conducted. Databases were searched from January 2003 to December 2022. We included randomized, pragmatic, or real-world clinical trials and observational studies. The primary outcome was medication adherence, secondary outcomes were efficacy in cardiovascular disease in primary and secondary prevention and safety. Results: From the 490 publications screened, 13 met the inclusion criteria and were incorporated into a comparative table Of those included, 70% were randomized controlled trials (RCTs) and 53.8% focused on secondary prevention. Most of the studies received a high and moderate quality rating. Self-report, pill counting and, the Morisky scale were the most frequent methods to evaluate adherence (84.6%). Compared with standard medication, the polypill improved overall medication adherence by 13%, with percen-tages ranging from 7.6% to 34.9%. Moreover, a potential benefit was also observed in reducing Major Adverse Cardiovascular Events (MACE), particularly in secondary prevention studies, with hazard ratios ranged between 0.43 to 0.76. Compared to standard care, the profile of side effects was similar. Conclusion: The polypill is an effective, safe, and practical strategy to improve adherence in people at risk of CVD. Although there is a demonstrated benefit in reducing MACE, predominantly in secondary prevention, there are still gaps in its efficacy in primary prevention and reducing total mortality. Therefore, the importance of obtaining long-term results of the polypill effect and how this strategy can be implemented in real practice.
引用
收藏
页码:605 / 615
页数:11
相关论文
共 50 条
  • [31] Beyond Cholesterol in the Primary Prevention of Cardiovascular Disease: Is The Polypill the Answer?
    Sanz G.
    Current Cardiovascular Risk Reports, 2011, 5 (1) : 38 - 44
  • [32] Adherence to cardiovascular medication: a review of systematic reviews
    Leslie, K. H.
    McCowan, C.
    Pell, J. P.
    JOURNAL OF PUBLIC HEALTH, 2019, 41 (01) : E84 - E94
  • [33] The polypill in cardiovascular prevention: successful through simplification? New study results on the benefit of the polypill strategy in primary and secondary prevention
    Despang, Patrick
    Schikora, Martin
    Doehner, Wolfram
    INNERE MEDIZIN, 2023, 64 (06): : 598 - 604
  • [34] Mobile phone text messaging to improve medication adherence in secondary prevention of cardiovascular disease
    Adler, Alma J.
    Martin, Nicole
    Mariani, Javier
    Tajer, Carlos D.
    Owolabi, Onikepe O.
    Free, Caroline
    Serrano, Norma C.
    Casas, Juan P.
    Perel, Pablo
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2017, (04):
  • [35] Polypill for cardiovascular disease prevention: Systematic review and meta-analysis of randomized controlled trials
    Mohamed, Mohamed M. G.
    Osman, Mohammed
    Kheiri, Babikir
    Saleem, Maryam
    Lacasse, Alexandre
    Alkhouli, Mohamad
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2022, 360 : 91 - 98
  • [36] Polypill strategy at the heart of cardiovascular secondary prevention
    Ibanez, Borja
    Castellano, Jose M.
    Fuster, Valentin
    HEART, 2019, 105 (01) : 9 - 10
  • [37] Polypill Therapy for Cardiovascular Disease Prevention and Combination Medication Therapy for Hypertension Management
    Narita, Keisuke
    Hoshide, Satoshi
    Kario, Kazuomi
    JOURNAL OF CLINICAL MEDICINE, 2023, 12 (23)
  • [38] Prospects for a Cardiovascular Disease Prevention Polypill
    Dabhadkar, Kaustubh C.
    Kulshreshtha, Ambar
    Ali, Mohammed K.
    Narayan, K. M. Venkat
    ANNUAL REVIEW OF PUBLIC HEALTH, VOL 32, 2011, 32 : 23 - 38
  • [39] Prevention of cardiovascular disease with a polypill - Reply
    Gaziano, Thomas A.
    Opie, Lionel H.
    Weinstein, Milton C.
    LANCET, 2007, 369 (9557): : 186 - 186
  • [40] The impact of dietary patterns on gut microbiota for the primary and secondary prevention of cardiovascular disease: a systematic review
    Yu, Junwen
    Wu, Yue
    Zhu, Zheng
    Lu, Hongzhou
    NUTRITION JOURNAL, 2025, 24 (01)